EMBioSys receives SBIR Direct-to-Phase II Award

EMBioSys is excited to announce that we have received a Direct-to-Phase II award from the National Cancer Institute.  This award will fund Efinia™ product development, manufacturing, and a first-in-human clinical trial for treatment of triple negative breast cancer along with adjuvant standard of care in patients at high risk for recurrence.  This work has the potential for saving the lives of patients with metastatic triple negative breast cancer who are not responsive to current standard of care.

Research reported in this announcement was supported by the National Cancer Institute of the National Institutes of Health under Award Number R44CA310518. The content is solely the responsibility of EMBioSys and does not necessarily represent the official views of the National Institutes of Health.